What is Aoti?
Headquartered in Oceanside, California, and Galway, Ireland, Aoti is a leader in the development of non-invasive Topical Wound Oxygen (TWO2) therapy. The company focuses on resolving severe and chronic wounds, a segment of the healthcare market that historically incurs substantial costs and presents significant patient quality-of-life challenges. By leveraging patented oxygen-delivery technology, Aoti provides a clinical alternative that accelerates healing processes, effectively positioning itself as a critical player in the medical device landscape. The firm's dual-location operational model allows it to bridge the gap between North American market reach and European research and development excellence, ensuring a comprehensive approach to global wound care delivery.
How much funding has Aoti raised?
Aoti has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Aoti
PPP
Public-Private Partnership
What's next for Aoti?
Following this late-stage capital infusion, Aoti is well-positioned to accelerate its commercial expansion and deepen its clinical research initiatives. The strategic deployment of these funds will likely focus on scaling the distribution of its TWO2 therapy, enhancing manufacturing capabilities to meet international demand, and potentially pursuing further clinical validation studies to solidify its competitive moat. As the company transitions into this next phase of maturity, the focus will remain on optimizing healthcare outcomes while simultaneously reducing the economic burden associated with chronic wound treatment. Investors and industry stakeholders will be monitoring the firm's ability to penetrate new geographic markets and integrate its technology into standard clinical protocols globally.
See full Aoti company page
